OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

Provencher, D M; Gallagher, C J; Parulekar, W R; Ledermann, J A; Armstrong, D K; Brundage, M; Gourley, C; Romero, I; Gonzalez-Martin, A; Feeney, M; Bessette, P; Hall, M; Weberpals, J I; Hall, G; Lau, S K; Gauthier, P; Fung-Kee-Fung, M; Eisenhauer, E A; Winch, C; Tu, D; MacKay, H J

Provencher, D M; Gallagher, C J; Parulekar, W R; Ledermann, J A; Armstrong, D K; Brundage, M; Gourley, C; Romero, I; Gonzalez-Martin, A; Feeney, M; Bessette, P; Hall, M; Weberpals, J I; Hall, G; Lau, S K; Gauthier, P; Fung-Kee-Fung, M; Eisenhauer, E A; Winch, C; Tu, D; MacKay, H J.

Affiliation

Provencher DM; Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
Gallagher CJ; Barts Health NHS Trust, London, UK.
Parulekar WR; Canadian Cancer Trials Group (CCTG), Queen's University, Kingston, Canada.
Ledermann JA; University College London Cancer Institute, London, UK.
Armstrong DK; Johns Hopkins University School of Medicine, Baltimore, USA.
Brundage M; Cancer Centre of Southeastern Ontario, Kingston, Canada.
Gourley C; Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Romero I; Secretaria del Área Clínica de Oncología Ginecológica, Instituto Valenciano de Oncología, València.
Gonzalez-Martin A; MD Anderson Cancer Center, Madrid, Spain.
Feeney M; University College London Cancer Institute, London, UK.
Bessette P; Gynecologic Oncology Division, Centre Hospitalier de l'Université de Montréal, Sherbrooke, Canada.
Hall M; Department of Obstetrics and Gynaecology, Mount Vernon Cancer Centre, Northwood, UK.
Weberpals JI; Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, Canada.
Hall G; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK.
Lau SK; Division of Gynecologic Oncology, Segal Cancer Center, SMBD Jewish General Hospital, McGill University, Montréal, Canada.
Gauthier P; Gynecologic Oncology Division, Centre Hospitalier de l'Université de Montréal, Sherbrooke, Canada.
Fung-Kee-Fung M; Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, Canada.
Eisenhauer EA; Canadian Cancer Trials Group (CCTG), Queen's University, Kingston, Canada.
Winch C; Canadian Cancer Trials Group (CCTG), Queen's University, Kingston, Canada.
Tu D; Canadian Cancer Trials Group (CCTG), Queen's University, Kingston, Canada.
MacKay HJ; Division of Medical Oncology & Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address: helen.mackay@sunnybrook.ca.

Ann Oncol ; 29(2): 431-438, 2018 02 01.

Article de En | MEDLINE | ID: mdl-29186319

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Traitement médicamenteux adjuvant / Carcinome épithélial de l'ovaire / Antinéoplasiques Type d'étude: Clinical_trials Aspects: Patient_preference Limites: Adult / Aged / Aged80 / Female / Humans / Middle aged Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2018 Type de document: Article Pays d'affiliation: Canada

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google